TITLE

MDS PROTEOMICS & ABGENIX DEVELOP ANTIBODY THERAPIES

PUB. DATE
August 2001
SOURCE
Worldwide Biotech;Aug2001, Vol. 13 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the collaboration of the MDS Proteomics and Abgenix Inc. to develop and commercialize antibody drugs.
ACCESSION #
4964879

 

Related Articles

  • Japanese rules hinder commercialization of publicly funded projects. Triendl, Robert // Nature Biotechnology;Apr2002, Vol. 20 Issue 4, p325 

    Reports on a deal announced by the nonprofit Kasuza DNA Research Institute in Japan to supply the Canadian company MDS Proteomics with human cDNA clones for protein interaction studies. Shift for the institute from sequencing toward functional genomics; Public sector genomics funding in Japan.

  • PEAKS of Interest.  // LC-GC North America;Sep2004, Vol. 22 Issue 9, p868 

    Presents news briefs related to chromatography in the United States as of September 2004. Delta Technical Products Co.'s launch of their website, a marketplace for new, used and refurbished laboratory equipment, chromatography instrument and replacement parts for the scientific community; MDS...

  • GENOMICS/PROTEOMICS.  // Drug Discovery & Development;Feb2002, Vol. 5 Issue 2, p31 

    Reports developments related to genomics and proteomics as of February 2002. Availability of the array information set from Affymetrix Inc.; Partnership between the University of Pittsburgh School of Medicine with UPMC Health System; Development of a technique for observing human cells in...

  • Abgenix and Pfizer add second antigen target.  // Chemical Market Reporter;11/02/98, Vol. 254 Issue 18, p15 

    Reports on Abgenix Inc. and collaborative partner Pfizer Inc.'s development of a second antigen target using Abgenix's XenoMouse technology. Terms of the agreement; Commercialization of antibody therapeutic products of Abgenix.

  • ABGENIX REPORTS NET LOSS OF $14.8 MILLION FOR 2ND QTR.  // Biotech Financial Reports;Sep2001, p5 

    Focuses on financial performance of Fremont, California-based biopharmaceutical firm Abgenix Inc. for the quarter ended June 30, 2001. Comparison with 2000 figures; Reasons for the net loss; Company highlights; Commercialization of fully human monoclonal antibody therapies for a variety of...

  • Abgenix Buys ImmGenics for $77MM.  // Chemical Market Reporter;10/02/2000, Vol. 258 Issue 14, p14 

    Reports on the acquisition of ImmGenics Inc. by biopharmaceutical company Abgenix Inc. Value of the deal; Benefits of the acquisition; Information on the technology of both companies.

  • Abgenix signs five year deal with Lonza.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p4 

    Reports on the manufacturing agreement between Slough, Great Britain-based drug company Lonza Biologics and Abgenix Inc. Terms and conditions of the agreement; Benefits of the agreement to Abgenix; Lonza's plan to expand its facilities in the United States.

  • US Financial accounts reports. Crocker, Glenn // Journal of Commercial Biotechnology;Spring2001, Vol. 7 Issue 4, p361 

    Provides information on the financial performance of pharmaceutical companies in the U.S. as of March 2001. Abgenix Inc.; Human Genome Sciences Inc.

  • New issues.  // Investment Dealers' Digest;03/15/99, Vol. 65 Issue 11, p30 

    Presents new companies which have offered shares on stock exchanges as of March 15, 1999. Companies including Abgenix Inc. and Argosy Education Group Inc.; Business type; Type of security; Number of shares offered; Price per share.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics